Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The . gov means it’s official. Federal government websites often end in VSports app下载. gov or . mil. Before sharing sensitive information, make sure you’re on a federal government site. .

Https

The site is secure. The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely V体育官网. .

. 2020 Jul 1;5(7):825-830.
doi: 10.1001/jamacardio.2020.1624.

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

Juyi Li  1 , Xiufang Wang  2 , Jian Chen  3 , Hongmei Zhang  4 , Aiping Deng  1
Affiliations

Association of Renin-Angiotensin System Inhibitors With Severity or Risk of Death in Patients With Hypertension Hospitalized for Coronavirus Disease 2019 (COVID-19) Infection in Wuhan, China

"VSports app下载" Juyi Li et al. JAMA Cardiol. .

Erratum in

  • Changes to Author Contributions.
    [No authors listed] [No authors listed] JAMA Cardiol. 2020 Aug 1;5(8):968. doi: 10.1001/jamacardio.2020.2338. JAMA Cardiol. 2020. PMID: 32813016 Free PMC article. No abstract available.

Abstract

Importance: Data are lacking whether patients with hypertension who are taking angiotensin-converting enzyme inhibitors (ACEIs) or angiotensin receptor blockers (ARBs) have increased severity or risk of mortality during hospitalization for coronavirus disease 2019 (COVID-19). VSports手机版.

Objective: To investigate the association between ACEIs/ARBs and severity of illness and mortality in patients with hypertension hospitalized for COVID-19 infection. V体育安卓版.

Design, setting, and participants: Retrospective, single-center case series of the 1178 hospitalized patients with COVID-19 infections at the Central Hospital of Wuhan, China, from January 15 to March 15, 2020. V体育ios版.

Main outcomes and measures: COVID-19 was confirmed by real-time reverse transcription-polymerase chain reaction and epidemiologic, clinical, radiologic, laboratory, and drug therapy data were analyzed in all patients. The percentage of patients with hypertension taking ACEIs/ARBs was compared between those with severe vs nonsevere illness and between survivors vs nonsurvivors. VSports最新版本.

Results: Of the 1178 patients with COVID-19, the median age was 55. 5 years (interquartile range, 38-67 years) and 545 (46. 3%) were men. The overall in-hospital mortality was 11. 0%. There were 362 patients with hypertension (30. 7% of the total group; median age, 66. 0 years [interquartile range, 59-73 years]; 189 [52. 2%] were men), of whom 115 (31. 8%) were taking ACEI/ARBs. The in-hospital mortality in the patients with hypertension was 21. 3%. The percentage of patients with hypertension taking ACEIs/ARBs did not differ between those with severe and nonsevere infections (32. 9% vs 30 V体育平台登录. 7%; P = . 65) nor did it differ between nonsurvivors and survivors (27. 3% vs 33. 0%; P = . 34). Similar findings were observed when data were analyzed for patients taking ACEIs and those taking ARBs. .

Conclusions and relevance: This study provides clinical data on the association between ACEIs/ARBs and outcomes in patients with hypertension hospitalized with COVID-19 infections, suggesting that ACEIs/ARBs are not associated with the severity or mortality of COVID-19 in such patients. These data support current guidelines and societal recommendations for treating hypertension during the COVID-19 pandemic. VSports注册入口.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: None reported.

References

    1. Wu Z, McGoogan JM. Characteristics of and important lessons from the coronavirus disease 2019 (COVID-19) outbreak in China: summary of a report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. Published online February 24, 2020. doi:10.1001/jama.2020.2648 - DOI - PubMed
    1. Guan WJ, Ni ZY, Hu Y, et al. ; China Medical Treatment Expert Group for COVID-19 . Clinical characteristics of coronavirus disease 2019 in China. N Engl J Med. Published online February 28, 2020. doi:10.1056/NEJMoa2002032 - DOI - PMC - PubMed
    1. Huang C, Wang Y, Li X, et al. . Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. doi:10.1016/S0140-6736(20)30183-5 - "V体育官网入口" DOI - PMC - PubMed
    1. Zhang H, Penninger JM, Li Y, Zhong N, Slutsky AS. Angiotensin-converting enzyme 2 (ACE2) as a SARS-CoV-2 receptor: molecular mechanisms and potential therapeutic target. Intensive Care Med. 2020;46(4):586-590. doi:10.1007/s00134-020-05985-9 - DOI - PMC - PubMed
    1. Zou X, Chen K, Zou J, Han P, Hao J, Han Z. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. Published online March 12, 2020. doi:10.1007/s11684-020-0754-0 - DOI - PMC - PubMed

Publication types

MeSH terms (VSports)

Substances